Skip to main content
Figure 3 | Lipids in Health and Disease

Figure 3

From: Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease

Figure 3

Dose-response (10 to 1000 mg/kg) for conversion of PPI-1011 to free DHA and DHA-containing plasmalogens (PlsEtn) and phosphatidylethanolamines (PtdEtn), 6 hours post oral dosing. Plasma levels are normalized to levels of the housekeeping metabolite PtsEtn 16:0/18:0. N = 6. 16:0 (palmitic acid); 18:0 (stearic acid); 18:1 (oleic acid); 22:6 (DHA).

Back to article page
\